Factors known to be of major prognostic significance for five-year survivorship had less influence than might have been expected when the ratio of observed to expected deaths -was considered for longer periods of follow-up. The effect of clinical staging (I, II, or III), though initially marked, largely disappeared by the 10th year of followup, and after allowing for age there was no evidence
Introduction
Increasing awareness of the natural history of breast cancer has had two major effects on the presentation of survival data. Firstly, it has led to the recognition that conventional fixed-time survival at five or 10 years is not synonymous with cure' and as a result there has been increasing use of life-table analysis.
Secondly, the fact that relapse can occur many years after initial treatment makes it necessary not only to continue follow-up for 20 years or more but also to allow for the normal mortality experience in the general population.'
Several authors have analysed survival data taking these considerations into account and have attempted to assess the curability of breast cancer by investigating whether the observed overall mortality of a group of patients eventually approached the expected mortality in a normal population of the same age. '-6 Easson and Russell could not identify a cured proportion of patients by the 15th year after initial treatment, though the observed mortality of their main study group of 1812 operable cases was only 1°' per annum in excess of expected mortality during the 10-15-year period. Nevertheless, they emphasised the need for a follow-up longer than 15 years. Brinkley and Haybittle, in a 25-year study of 704 women, suggested that after 21 years observed and expected mortalities were the same and interpreted this to mean that 300h of women with stage I and II disease were cured. In contrast, Duncan and Kerr concluded that patients with tumours larger than 3 cm but with no evidence of spread beyond the breast had a normal life expectancy 12 years after treatment, but for patients with smaller tumours normal life expectancy might not be observed until after 20 years.
In spite of these estimates of curability, analysis of the deaths that occur more than 20 years after treatment have shown that breast cancer remains significantly more common as a cause of death than in the general population. Of all women who die after developing cancer of the breast, 80-85o" do so from their disease.7 8 A cured group, if it exists, may therefore be smaller than that suggested by Brinkley and Haybittle.
Little information exists on the effect that various prognostic factors might have on curability. Brinkley and Haybittle concluded that patients with stage I and II disease had a higher probability of cure, while Duncan and Kerr studied the effect of tumour size but only for cases with no evidence of spread beyond the breast. We know of no previous study relating the menstrual status of the patient dt presentation to the curability of the disease in spite of its well-recognised significance in terms of fixed-time survival rates. 9-"
We report here a study of survival in a series of 3878 patients in which we evaluated the influence of three prognostic variables -stage of the disease, tumour size, and menstrual status-on the curability of breast cancer.
Patients and methods
A computer-based data file was established by abstracting clinical information from the case records of all patients with breast cancer referred to the department of radiotherapy, Edinburgh, from 1 January 1954 to 31 March 1964. The patient's status was established each year on the anniversary of first treatment and cases were dismissed from follow-up at 20 years if there was no recurrent disease. Cases referred for the management of recurrent disease were excluded from this review as were cases treated elsewhere but referred for follow-up.
Of the original 3924 cases seen in this period, 46 were excluded from this study: two were initially treated before 1954, four had bilateral disease, and 40 were aged over 85 years at presentation. This left 3878 cases for analysis.
Over the period of the review two different staging systems were used. All cases were therefore restaged by the international TNM system.'2 13 There was insufficient detail to permit staging by TNM criteria in 85 cases. Menstrual status at presentation was known for 3680 patients on the basis of the patient's statement as to whether menstrual bleeding was occurring or not, irrespective of its regularity. They were subdivided into three groups: 1064 who were premenopausal, 450 who were menopausal-that is, less than five years past the menopause-and 2166 who were postmenopausal-more than five years past the menopause.
During the period under review the treatment policy of the department of radiotherapy, Edinburgh, was for simple mastectomy of the breast to be followed by postoperative radiotherapy.14 Seventy-five percent of all patients in this series, and over 90<, of those with stage I or II disease, were treated in this way. We did not restrict our analysis to those treated by simple mastectomy and x-ray therapy since we considered that more reliable data on overall survival and the effects of staging were obtained by including all patients.
In the survival analysis patients were removed from further follow-up on reaching their 85th birthday. This Although each death was classified as due to either breast cancer or other causes on the basis of available knowledge including the review of hospital records and death certificates, we acknowledge that this information is not sufficiently reliable or objective2 and hence is included only as secondary evidence.
Results and comment
OVERALL SURVIVAL EXPERIENCE Figure 1 shows the life table survival curve for all 3878 patients.
Median survival was 4-6 years, with an estimated 310% surviving 10 years and 18%'o surviving 20 years. The international stage of the disease had a pronounced effect on survival: the median survival times were 9 7 years, 6 6 years, 2-9 years, and 0-7 years for stages I-IV respectively. The influence of different staging criteria on the presentation of survival data in this series has been dealt with in detail elsewhere."3 100 > 50- Stage I-Mortality was low initially (4-5%/) in the first year of follow-up, rising to a peak of 9-4%" in the 4th year, after which the curve for stage I disease declined to an average of 4 4°' over the 17th to 20th years.
Stage II-The mortality in the 1st year was also low (5-3%' Figure 4 shows the* ratio of observed to expected deaths for the series as a whole. The ratio fell from 8 3 in the first year to 2 6 in the 10th year of follow-up. Thereafter, because of the smaller numbers left, the ratio varied from year to year but remained greater than one throughout. More reliable information was obtained when we used periods of follow-up longer than one year, as in table I. There was a large excess mortality among the patients up to 15 years after initial treatment. From 15 to 20 years there was still a 58%O excess mortality, which was very highly significant (P < 0-001), and the 95%, confidence limits indicated that the real excess for all breast cancer patients at this stage was somewhere between 25%' and 98%o. Even after 17 years' follow-up there was still some evidence of excess mortality (P < 0 05), though the numbers thereafter were too small for definite conclusions.
Thus it seems unlikely that patients in this series as a whole could be considered cured after 17 years' follow-up, but more need to be followed up to 20 years before deciding for certain. Although 141 patients were still alive on the 20th anniversary of first treatment, a further 625 patients are still alive but have been followed up for less than 20 years, and of these, 254 have been followed up for less than 15 years. For the purpose of statistical analysis an additional 116 patients were removed from further follow-up once they reached their 85th
birthday.
An alternative method of expressing the excess mortality of breast cancer patients (the difference between observed and expected deaths) is in terms of the number of woman-years of follow-up-that is, as an excess death rate per year (see table I ). Thus at 15-20 years the excess death rate was 18 8 per 1000 woman-years, or just under 2% a year. expected. This 28%/' excess of deaths was significant (one-tail test P < 005) but was considerably less than the 58% excess when the relapsed patients were included. Hence, for patients who were diseasefree at 15 years there is a somewhat more optithistic outlook. Even so 11 of the 54 deaths were attributed to breast cancer, which was still considerably more than expected.
Similarly, when patients with a disease-free interval of under 10 years were excluded, the excess of observed to expected deaths 10-15 years after initial treatment fell to 44%h compared with the earlier figure of 116% when relapsed patients were included. Table II shows the ratio of observed,to expected deaths according to the international stage of the disease. After 10 years' follow-up the ratios for stages I, II, and III were very similar. A goodness of fit test (X2=0-54; 2 DF) showed no significant difference between these ratios, indicating that after 10 years there Effect of menstrual status-This is shown in table IV for the three categories already defined. Stage IV cases were excluded since their survival was so very different from that of non-metastatic patients. Nevertheless, stage IV disease was significantly more common in postmenopausal (14"lo) than premenopausal women (8°0). For the early periods of follow-up the ratio of observed to expected deaths was greatly increased in premenopausal women because mortality from causes other than breast cancer was extremely low in that age group. This was an indication of the large loss of life expectancy in younger patients with breast cancer but did not imply that their disease was more aggressive than that in older women. For the premenopausal patients in the 15-20-year follow-up period the excess of deaths observed over expected was still significant (24 v 9-2; P < 0-01); half of these deaths were attributed to breast cancer. For all postmenopausal patients (including those initially in the menopausal group) there was a smaller excess (45 v 35-8; P < 0-1), which was of marginal significance. Since 18 of these deaths were attributed to breast cancer we cannot say that cure was achieved after 15 years in postmenopausal patients.
Effect of clinical staging-
The position was further clarified by considering patients who were disease-free at 15 years. The observed mortality in 204 patients in this category was 33 compared with 30-28 expected, a ratio of 1-09, which was very close to the desired ratio of unity. This still cannot be interpreted in a totally optimistic way since eight of these deaths were attributed to breast cancer. TI he excess death rates shown in table IV give some additional information about the effects on survival of menstrual status at presentation. In the first five years of follow-up menopausal patients had an excess mortality more than 30ttO greater than that occurring in the premenopausal and postmenopausal groups.
Over the next 10 years excess mortality was similar for all three groups, but at 15-20 years premenopausal patients had the highest excess death rate. One additional observation regarding the premenopausal group concerns patients under the age of 35 at presentation. This was a small group of 101 patients, only 44", of whom survived five years. The situation improved thereafter, with 54% of five-year survivors still alive after 20 years compared with 37% of older patients.
Discussion
The analysis of long-term follow-up data in patients with breast cancer has led some authors to conclude that some women are cured of breast cancer, cure being defined as the achievement of mortality equal to that in the general population.3-Nevertheless, both The standard of comparison in this study was the Scottish national population, whereas the patients were predominantly from the Edinburgh area, which has a slightly lower mortality. This may mean that the calculated expected deaths are slightly greater than they should be, but such -potential bias is very small compared with the mortality risks under consideration.
EFFECT OF CLINICAL STAGE When only fixed-time survival is considered significant differences in survival between the different stages of the disease persist up to 20 years after treatment.'3 It is interesting to compare this fact with the data presented in figure 2 and table II. From the 10th year onwards there was no clear distinction between patients classified as stage I and those classified as stage II in terms of the mortality of the disease.
The heterogeneity of the group of patients with stage III disease is emphasised by a mortality of 520, in the first three years, but those that survived three years have a reasonable prognosis and from 15 years onwards they assumed the same annual mortality of around 50o as did patients with stage I or stage II disease.
Considering the period 10-20 years as a whole, patients with stage II disease experienced a slightly higher mortality. Over this period the ratio of observed to expected deaths was 195, 2 17, and 2 02 for stages I, II, and III respectively.
EFFECT OF TUMOUR SIZE
The correlation between tumour size and survival from breast cancer is well documented.' 13 -0 The effect of this factor on curability was reported by Duncan and Kerr, but their study was restricted to patients with disease confined to the breast on clinical examination. Since, in an unselected series, the proportion of tumours clinically confined to the breast falls progressively as tumour size increases, larger tumours which have no signs of spread may be of a particularly favourable kind. We have therefore examined the effect of size on curability for all cases in stages I and II. The results differ somewhat from those of Duncan and Kerr in that for no tumour size considered did the ratio of observed to expected deaths fall below 1 [15] [16] [17] [18] [19] [20] years from treatment and that postmenopausal patients were in fact the only group that came close to achieving cure in the 20 years.
Patients in the menopausal group are conventionally regarded as carrying the poorest prognosis. In our series this was so in the first five years, when the age-corrected survival (52"0,) of menopausal women was significantly lower (P <0 01) than that of the premenopausal group (62%') and the postmenopausal group (61°h). This difference disappeared with longer follow-up, and the smallest excess mortality rate inthe 10-20-yearfollow-up, periods occurred in this group. Our findings have not confirmed recent suggestions that breast cancer is a more aggressive disease in older women.11 25 CONCLUSION Our analysis of survival in a group of patients with breast cancer first treated from 1954 to 1964 and followed up through 1976 has failed to reveal any group of patients who may be considered cured within 20 years, though for postmenopausal patients there is some cause for optimism if they are disease-free after 15 years. Treatment by simple mastectomy and radiotherapy is generally accepted to give results equivalent to more radical surgery plus or minus radiotherapy.26 It seems reasonable to conclude that consideration of other series treated by other local techniques would show a similar lack of evidence for a cured group of cases. It remains to be seen whether the recent approach of combining surgery plus or minus radiotherapy with adjuvant chemotherapy or hormone therapy will significantly alter this picture. These results also raise questions about the need for a radical approach to the treatment of the primary tumour. Since there is no evidence that such an approach is associated with the cure of the disease trials of more conservative primary treatment may therefore be justified.
